Review

The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features

Grant L. Iversona,*, C. Dirk Keeneb, George Perryce and Rudolph J. Castelland

aDepartment of Physical Medicine and Rehabilitation, Harvard Medical School, Spaulding Rehabilitation Hospital, MassGeneral Hospital for ChildrenTM Sports Concussion Program, and Home Base, A Red Sox Foundation and Massachusetts General Hospital Program, Boston, MA, USA
bDepartment of Pathology, Division of Neuropathology, University of Washington School of Medicine, Seattle, WA, USA
cCollege of Sciences, University of Texas, San Antonio, San Antonio, TX, USA
dCenter for Neuropathology, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA

Handling Editor: Massimo Tabaton

Accepted 31 August 2017

Abstract. There is tremendous recent interest in chronic traumatic encephalopathy (CTE) in former collision sport athletes, civilians, and military veterans. This critical review places important recent research results into a historical context. In 2015, preliminary consensus criteria were developed for defining the neuropathology of CTE, which substantially narrowed the pathology previously reported to be characteristic. There are no agreed upon clinical criteria for diagnosis, although sets of criteria have been proposed for research purposes. A prevailing theory is that CTE is an inexorably progressive neurodegenerative disease within the molecular classification of the tauopathies. However, historical and recent evidence suggests that CTE, as it is presented in the literature, might not be pathologically or clinically progressive in a substantial percentage of people. At present, it is not known whether the emergence, course, or severity of clinical symptoms can be predicted by specific combinations of neuropathologies, thresholds for accumulation of pathology, or regional distributions of pathologies. More research is needed to determine the extent to which the neuropathology ascribed to long-term effects of neurotrauma is static, progressive, or both. Disambiguating the pathology from the broad array of clinical features that have been reported in recent studies might facilitate and accelerate research—and improve understanding of CTE.

Keywords: Concussion, neurodegenerative, neuropathology, tau

INTRODUCTION

Chronic traumatic encephalopathy (CTE) has been recognized, but not well studied, for more than 80 years, and the large majority of publications in the past century are case studies [1–6]. CTE was initially conceptualized as a neurological disorder affecting boxers who had tremendous exposure to neurotrauma [1, 2]. Martland [1] described the clinical features as mostly including gait disturbance, dysarthria, tremor, and cognitive impairment. In the 1930s, the syndrome was referred to as traumatic encephalopathy [7] and dementia pugilistica [8]. In the late 1940s,
Critchley referred to it as CTE [9] and in 1957 he referred to it as chronic progressive traumatic encephalopathy [10]. In 1969, the first and only large clinical study of chronic neurotrauma in boxers was published by Roberts as a book. He selected an age-stratified random sample of 250 retired boxers from a cohort of 16,781, located and clinically examined 224, and identified 17% as having the syndrome (i.e., 11% as having a mild form of the syndrome and 6% as having severe traumatic encephalopathy). Omalu and colleagues published the first description of CTE in a retired National Football League (NFL) player in 2005 [11], with additional case studies published in 2006 [12] and 2010 [13]. In 2009, McKee and colleagues described three additional cases, one retired football player and two boxers, within their review of 48 known cases in the world literature [14].

Omalu and colleagues introduced four neuropathological “phenotypes” in 2011 [15], and McKee and colleagues introduced four neuropathological “stages” of CTE in 2013 [16]. These descriptions of phenotypes and stages vary in the diversity and severity of neuropathology. These phenotypes and stages largely underlie the theory and assumption that the pathology and clinical features are progressive. Moreover, the stages vary as a function of age—and Stage III and IV cases often have co-morbid neurodegenerative diseases [16].

In Roberts’ large study of boxers in the 1960s, he reported that most with the syndrome had a static course, there were anecdotal cases of improvement after retirement from boxing, and a small subgroup appeared to have a progressive course greater than expected from aging [2]. Decades later, Jordan echoed the conclusions of Roberts and noted that it was unclear whether worsening of chronic brain injury in boxers reflected a progressive neurodegenerative disease, the aging process superimposed on a single injury of any severity [23] or repetitive subconcussive blows can cause CTE [13]. The confident assertions of causation by some researchers stand in juxtaposition with the fact that the etiologies of much better characterized sporadic neurodegenerative diseases, each of which is inexorably progressive, are mostly unknown. This article discusses the complexity of the current conceptualization of CTE pathology and clinical features attributed to that pathology.

NEUROPATHOLOGY

In publications from 2005–2015, CTE has been described as a progressive neurodegenerative disease characterized by a broad and diverse range of both macroscopic and microscopic neuropathology. The gross neuropathology, described as “characteristic” of CTE, includes 1) frontal and temporal atrophy, thinning of the hypothalamic floor, shrinkage of the mammillary bodies, pallor of the substantia nigra, hippocampal sclerosis, and reduction in brain mass; 2) enlarged ventricles; and 3) cavum septum pellucidum with or without septal fenestrations [14, 24, 25]. Microscopic features described as characteristic have included 1) localized neuronal and glial accumulations of phosphorylated tau (p-tau) with varying microscopic morphologies, involving perivascular areas of the cerebral cortex and sulcal depths, and with a preference for neurons within superficial cortical laminae; 2) multifocal axonal varicosities involving deep cortex and subcortical white matter; 3) variable and often absent amyloid-β (Aβ) deposits; and 4) TDP-43-positive inclusions and neurites [14, 24, 25]. A variable distribution and quantity of tau pathology, and the accumulation of other altered proteins such as Aβ, α-synuclein (αS), and transactive response DNA (TDP) binding protein 43-immunoreactivity, occurs with human aging and other distinct diseases, and can also be found in people who are cognitively normal [26]. Most of the above-mentioned gross and microscopic features have not, as yet, been independently verified as specific to CTE [27–30], and virtually all are associated with aging, other neurological diseases, or both.

Prior to 2015, there were no agreed upon neuropathological criteria for CTE, and the criteria put forward by the two research groups in the US differed...
To address this problem, a panel of seven neuropathologists, convened by the National Institutes of Health (NIH), were provided 10 cases of advanced CTE (two with Stage III and eight with Stage IV pathology [16]) and 15 cases with primary tau-related neurodegenerative diseases to examine blindly [30]. The 10 cases of presumptive CTE were former professional athletes, between the ages of 60 and 85, selected by researchers from Boston University. The pathologists were provided a presumptive a priori definition of the neuropathology of CTE from Boston University (see online supplementary material 1 in the original article). They then examined the cases without access to demographic information, clinical history, or gross neuropathologic data, and listed their diagnoses. They then met in person to further refine their interpretations and discuss the overall findings.

Through their work, preliminary consensus criteria for the neuropathology of CTE were developed [30]. It should be noted that the panel did not fully adopt the a priori neuropathological criteria (i.e., online supplementary material 1), but they did produce a set of criteria that were similar. They defined a single “pathognomonic” criterion for CTE as an accumulation of abnormal p-tau in neurons, astrocytes, and cell processes around small vessels in an irregular pattern at the depths of the cortical sulci [30]. This finding represents a distribution of p-tau that is believed to differ from that seen in aging and neurodegenerative diseases. The consensus report did not indicate that p-tau increases quantitatively on a whole brain level, greater than what would be expected from aging, pre-clinical neurodegeneration, or comorbid neurodegenerative disease. Rather, the pathognomonic feature relates to specific distributions, not overall burden, of pathology.

They also identified supportive criteria as follows: “(1) abnormal p-tau immunoreactive pretangles and NFTs preferentially affecting superficial layers (layers II–III), in contrast to layers III and V as in AD; (2) in the hippocampus, pretangles, NFTs or extracellular tangles preferentially affecting CA2, and pretangles and prominent proximal dendritic swellings in CA4. These regional p-tau pathologies differ from the preferential involvement of CA1 and subiculum found in AD; (3) abnormal p-tau immunoreactive neuronal and astrocytic aggregates in subcortical nuclei, including the mammillary bodies and other hypothalamic nuclei, amygdala, nucleus accumbens, thalamus, midbrain tegmentum, and isodendritic core (nucleus basalis of Meynert, raphe nuclei, substantia nigra and locus coeruleus); (4) p-Tau immunoreactive thorny astrocytes at the glial limitans most commonly found in the subpial and periventricular regions; and (5) p-Tau immunoreactive large grain-like and dot-like structures (in addition to some threadlike neurites)” [30]. Additional pathologies that were considered supportive of the diagnosis were as follows: “(1) macroscopic features: disproportionate dilatation of the third ventricle, septal abnormalities, mammillary body atrophy, and contusions or other signs of previous traumatic injury; and (2) TDP-43 immunoreactive neuronal cytoplasmic inclusions and dot-like structures in the hippocampus, anteromedial temporal cortex and amygdala” [30]. The consensus panel acknowledged the limitation of using only “moderate to late stage” CTE to develop the consensus criteria. Interestingly, the frequent comorbidities in advanced stage CTE might actually hamper the interpretation compared to early stage CTE, which should be more easily separated from both age-related changes and other neurodegenerative diseases. The consensus panel did not adopt the four neuropathological phenotypes [15] or stages of CTE [16], and indicated that the preliminary criteria were a “first step along the path to standardizing the neuropathology of CTE” [30]. Moreover, they did not address whether CTE was a progressive neurodegenerative disease, or whether there were known or predictable clinicopathologic correlations. Instead, they examined whether CTE could be separated neuropathologically from other pathologies.

CTE-LIKE NEUROPATHOLOGY IN AGING AND OTHER DISEASES

The consensus criteria for CTE [30] are mostly similar to, but have some important differences from, the neuropathological criteria described in papers between 2005 and 2015. Many of the gross and microscopic neuropathological features described in past studies were not included in the definition. Moreover, the presumptive diagnostic criteria provided to the panelists prior to the consensus conference were not adopted in whole. For example, the first presumptive criterion, “perivascular foci of p-tau immunoreactive neurofibrillary tangles (NFTs) and astrocytic tangles (ATs) in the neocortex” (see online supplementary material 1) was not adopted—presumably because this criterion is not unique to CTE. P-tau in these regions has recently been described in the postmortem brains of patients who had ALS [31],
temporal lobe epilepsy [32], and multiple system atrophy [33] but no known history of participation in contact sports or neurotrauma. Gao and colleagues recently described a case of a man with ALS and no known history of neurotrauma who had CTE-like pathology in both depths of sulci and perivascular regions [34].

Perivascular, subpial, and periventricular p-tau immunoreactive NFTs and astrocytic tangles in the neocortex have been reported to be characteristic of both primary age-related tauopathy (PART) [35] and age-related tau astrogliopathy (ARTAG) [36]. PART is characterized by neurofibrillary degeneration most notable in medial temporal lobe, basal forebrain, brainstem, olfactory bulb, and cortex, in association with little or no amyloid-β accumulation—and PART may or may not be associated with cognitive impairment. PART refers to neuronal tau pathology and ARTAG is characterized by astrocytic tau pathology, although they are not mutually exclusive, and appear to be more a manifestation of age than a subtype of neurodegenerative disease. The authors describing ARTAG appear to emphasize p-tau in the sulcal depths as the most specific feature distinguishing CTE and ARTAG, stating “ARTAG has features that overlap those of CTE, including the accentuation of tau pathology around small cerebral vessels and in subpial and periventricular areas. On the other hand, tau pathology, including neuronal and astroglial, in CTE is more abundant in the depths of the cerebral sulci, especially in early stages, an aspect that has not been reported in tau astrogliopathy in the aging brain.” This distinction was not made prior to 2015, so in some past published cases PART and ARTAG neuropathology was likely interpreted as CTE-specific neuropathology. Historical cases of dementia pugilistica are interesting in this regard, in that the pathological descriptions in some cases appear indistinguishable from PART [6], consistent with Jordan’s hypothesis that dementia pugilistica may in some cases represent the aging process superimposed on fixed structural pathology [17].

In a large-scale post-mortem study of CTE in the United Kingdom, Ling and colleagues screened 268 cases and identified pathology consistent with recent descriptions of CTE in 32 (11.9%) [37]. History of traumatic brain injury, with or without loss of consciousness, was present in nearly all cases (i.e., 93.8%). Only a minority, however, had known participation in sports (34%), and 18.8% were military veterans. Remarkably, of those 32 cases, 13 were women (40.6%). The majority of the screened cases met neuropathological criteria for other neurodegenerative diseases, although some were control subjects. The rates of CTE pathology stratified by neurodegenerative diseases were as follows: progressive supranuclear palsy = 24%, PD = 16%, AD = 10%, corticobasal degeneration = 7.4%, frontotemporal lobar degeneration = 4.2%, multiple system atrophy = 2%, and control subjects over the age of 60 = 12.8%. This study was completed before the NIH consensus criteria were published, so it is possible that the rates would be different (i.e., lower) if those criteria had been applied. It is not known whether, or the extent to which, ARTAG and PART pathology was conceptualized as CTE pathology in that study. In another large-scale neuropathology study [38], 21 of 66 former athletes (31.8%) had tau pathology suggestive of CTE. In contrast, none of the 198 cases who were not former athletes showed CTE pathology, including a subgroup of 33 cases who had a history of a single traumatic brain injury. Nearly all (95%; 20/21) of those with CTE pathology had primary neuropathological diagnoses of a neurodegenerative disease such as AD, frontotemporal dementia, Lewy body disease, or ALS. Of the former boxers, 2 of 9 (22.2%) had CTE pathology and 16 of 43 former football players (37.2%) had CTE pathology.

Koga and colleagues [33] examined 139 autopsy-confirmed cases of multiple system atrophy for pathological evidence of CTE. Using the consensus criteria, they identified CTE pathology in 8 cases (6%). All were men, but only four had a history of participation in sports (three in football and one in basketball). The authors were careful to differentiate cases of ARTAG (10 cases) from CTE in this study, and noted that ARTAG pathology in past studies might have been mistaken for CTE pathology. The authors speculated that the CTE pathology could be related to falls associated with having multiple system atrophy—but there was no reported statistical association between falls and CTE pathology in that study. In addition, the authors did not report other evidence that might be associated with falls and neurotrauma, such as structural pathology (e.g., contusions).

Noy and colleagues [39] examined 111 brains in a routine neuropathology service in Canada for the presence of CTE pathology. The subjects were between the ages of 18 and 60, and they were from a non-selected community-based neuropathology referral base. They set their cutoff age at 60 to reduce the confounding effects of aging and preclinical neurodegenerative diseases. They identified CTE pathology, based on the staging system of
McKee et al. [16], in 4.5% (three cases of Stage I and two cases of Stage II). However, they made the important observation that there is no lower bound for classifying Stage I CTE pathology, so if they included tiny amounts of pathology characteristic of Stage I, an additional 34 cases were identified (30.6% of the sample). Therefore, of the total sample, 35.1% had some degree of mild CTE pathology. Only one subject had a history of sports participation, and there were three women in the sample. Factors that were associated with the presence of CTE pathology were age, history of traumatic brain injury, and substance abuse. Some of the cases had no known history of traumatic brain injury. There was no association between CTE pathology and psychiatric illness in this sample.

**NEURODEGENERATION SEPARATE FROM CTE OR CO-OCCURRING WITH CTE**

If one examines the online supplementary material that accompanied the study by McKee and colleagues that describes the stages of CTE [16], it is apparent that some cases conceptualized as having pure CTE also have other proteinopathies (e.g., non-specific p-tau, amyloid-β, α-synuclein, and TDP-43), which raises the possibility of early or preclinical neurodegenerative disease distinct from the pathology attributed to CTE. Therefore, “pure CTE” might be a misnomer in some cases, especially for cases with lesser amounts of region-specific p-tau who might have some degree of PART or ARTAG pathology that is separate from CTE. It is unknown if CTE pathologic lesions begin as purely glial and then progress to involving neurons. If so, ARTAG could be a precursor lesion to CTE pathology in some cases, or CTE pathology could mimic ARTAG in the mildest examples. Without good experimental models, it is virtually impossible to know how pathology progresses.

Neurodegenerative diseases exist in “pure” forms, but it is well understood that polypathology and disease comorbidities are common in those with AD, Lewy body disease, cerebrovascular disease, and hippocampal sclerosis. It can be difficult to determine the extent to which each pathological change contributed to a given person’s clinical symptoms and course without rigorous clinicopathologic correlation. Even then, correlation between proteinopathy and clinical signs can be limited [40]. It is now well established that a large percentage of former athletes identified as having CTE neuropathology also have neuropathology associated with age related neurodegenerative diseases such as AD, PD, Lewy body disease, hip- pocampal sclerosis, and ALS [14, 41–44] to the extent that they meet full neuropathological criteria for an alternative, well-characterized neurodegenerative disease [16]. Often, however, whenever the pathology of CTE is identified, regardless of the amount, the case is conceptualized as CTE, when in fact it might be more appropriate to conceptualize the person as having another neurodegenerative disease with small amounts of CTE neuropathology. A recent case report emphasizes this problem [45]. In fact, in studies involving traditional brain banks, the majority of people identified as having CTE pathology have only mild forms of the pathology (e.g., Stage I or Stage II), in association with a separate and primary relentlessly progressive and fatal neurodegenerative disease [33, 37, 38].

**IS THE NEUROPATHOLOGY OF CTE INEXORABLY PROGRESSIVE?**

Researchers have not established that the neuropathology defining CTE is inexorably progressive. In fact, some accumulating evidence is inconsistent with the theory that CTE is a progressive neurodegenerative disease. It is well established that some people who have large exposures to repetitive neurotrauma, such as retired professional football players or boxers, had only Stage I or Stage II CTE at the time of their deaths [16], and some of these individuals died in their 80s. This suggests that the kinetics of p-tau accumulation in some people is either non-existent or limited. In the previously discussed large-scale postmortem study of CTE in the United Kingdom, Ling and colleagues screened 268 cases and identified pathology consistent with CTE in 11.9% [37]. All cases were considered Stage I or Stage II based on the staging system of McKee and colleagues [16], and their mean age of death was 81.0 years. The authors assumed that most of the cases with CTE pathology were likely to be clinically asymptomatic. Given the limited pathology (Stage I or Stage II) late in life, a progressive tauopathy, and associated psychiatric or neurologic disease, appears unlikely in these cases.

In another study [38], 21 of 66 former athletes (31.8%) had tau pathology suggestive of CTE. All cases had a separate neurodegenerative disease. Of the 21 cases of CTE pathology, 14 (66.7%) had Stage I or II pathology based on the staging system of McKee.
and colleagues [16], suggesting that if the pathology is progressive it had not progressed to a later stage in most people, in the setting of a primary neurodegenerative disease with extensive proteinopathy that began many years after athletic exposure (and possibly after the deposition of p-tau in a CTE-like distribution). Of the 7 with Stage I pathology, two died with ALS. Of the 5 who did not have ALS, 4 were over the age of 70 at the time of their death, suggesting that the CTE pathology had not or had minimally progressed over their adult lives. Moreover, if the CTE pathology represented a separate progressive neurodegenerative disease, it would be expected that former athletes with CTE, compared to those without CTE, would have earlier onset clinical features of disease and earlier death. However, there were no differences between groups in disease onset, disease duration, or age at death [38].

As previously discussed, Koga and colleagues [33] examined 139 cases of multiple system atrophy and identified CTE pathology in 6%. They classified two cases as Stage I, five as Stage II, and one as Stage III. In the Canadian series of 111 brains from a community autopsy service [39], only 4.5% had Stage I or Stage II CTE pathology, and there were no cases of Stage III or IV pathology. Nearly one in three subjects (30.6%), however, had a very small amount of p-tau which was conceptualized as less than Stage I pathology. In summary, there is emerging evidence from several research groups that CTE pathology might not be inexorably progressive.

**ARE THE CLINICAL FEATURES KNOWN?**

There are no agreed upon or validated clinical criteria for CTE, although proposed criteria have been published by Jordan [46], Victoroff [47], and Montenigro and colleagues [21]. In the past, based on studies in boxers with extensive neurotrauma exposure, slurred and dysarthric speech, gait problems, Parkinsonism, cognitive impairment, and dementia were considered clinical features [2, 48, 49]. Some descriptions of historical cases also included psychiatric illnesses, severe substance abuse, and other medical or neurological problems. Over the past decade, the clinical features attributed to CTE have been expanded greatly and include virtually any mental health or neurological symptom or problem present prior to death, such as 1) depression and anxiety [15, 16, 24]; 2) suicidality [16, 18–20, 22–24]; 3) personality changes, anger control problems, and violence [15, 16, 24]; 4) poor financial decisions, financial problems, and bankruptcy [15]; 5) marital problems, separation, and divorce [22]; 6) headaches [14–16]; 7) generalized body aches and pain [15]; 8) insomnia [22]; 9) Parkinsonism [11, 16, 24]; 10) mild cognitive impairment (MCI) [15, 16, 24]; 11) dementia [15, 16, 24]; and 12) motor neuron disease resembling ALS [43]. Although suicide is often reported to be a clinical feature of CTE in case studies and general review papers [13, 16, 18–20, 22–24], several reviews focused specifically on suicide [50–53], one retrospective historical case review study [54], and one epidemiological study [55] have concluded that there is minimal or no scientific evidence to support this assertion.

Many of the clinical symptoms that have been attributed to CTE pathology are common in the general population (e.g., depression, anxiety, anger, financial problems, marital problems, headaches, bodily pain, and insomnia). Of these, depression is often ascribed to CTE pathology, or that CTE pathology causes depression. Such an assertion should be considered a hypothesis to be tested, not an established clinicopathological correlation or causal association. The theoretical mechanisms by which heterogeneous psychological, functional, and biochemical disturbances underlying depression relate directly to the accumulation of insoluble post-translationally modified proteins have not been discussed or resolved in prior studies. Further, a correlation between CTE pathology and depression has not been established. Moreover, in psychiatry depression is conceptualized as heterogeneous, multifactorial in causation, and it is believed to arise from the cumulative effects [56–58] of genetics [59–62], adverse events in childhood [63–66], and ongoing life stressors [67–70]. In the general population, depression is associated with a wide range of health, mental health, and neurological conditions, such as 1) chronic pain [71–75]; 2) headaches and migraines [76–79]; 3) diabetes [80–82]; 4) low testosterone [83–85]; 5) cardiovascular, cerebrovascular, and small vessel ischemic disease [86–92]; 6) PD [93]; 7) MCI [94–96]; and 8) AD [97]. Therefore, former athletes, military veterans, and civilians who have neuropathology characteristic of CTE might experience depression for a broad range of reasons, similar to people in the general population who have no history of athletic participation or military service.

Clearly, people with psychiatric, neurological, and neurodegenerative diseases have the same symptoms
and problems as those described in the CTE case studies. Moreover, if one assumes that CTE pathology clinically manifests decades after exposure (something that has not been demonstrated by prospective studies) the likelihood is maximized that any health, psychiatric, or neurological condition that affects a person’s brain and behavior could be erroneously attributed in whole or part to the CTE pathology. Simply put, if a former athlete developed depression in association with life stress, marital problems, and chronic pain, that person could be incorrectly assumed to be showing the clinical features of a “progressive neurodegenerative disease,” the diagnosis of which could further exacerbate this psychiatric condition. The neuropathology consensus group convened by the NIH noted that it is especially important to understand that it is not yet possible to correlate clinical symptoms or future brain health with the signature pathologic feature of CTE [30]. Research is needed to determine whether neurotrauma associated with athletic participation intrinsically causes localized and variable deposits of post-translationally modified and insoluble p-tau, and whether those protein deposits cause specific symptoms or syndromes, such as depression.

ARE THE CLINICAL FEATURES PROGRESSIVE?

In 1928, Martland reported that some cases remain mild and do not progress, and other cases progress to advanced Parkinsonism and dementia. Carroll, in 1936, described the punch-drunk syndrome as evolving during one’s boxing career, progressing for a year or so after, and then becoming stationary. He noted that some boxers, however, deteriorated and needed to be institutionalized [98]. In contrast, in 1957 Critchley emphasized that the condition is gradually progressive [10]. Similarly, in 1963, Mawdsley and Ferguson [4] reported 10 cases of boxers, some of whom noticed the onset of neurological problems, such as slowing down and have slurred speech, while still actively fighting. Others noticed neurological deterioration years after they retired. These cases had a progressive course. In Roberts’ large-scale study of more than 200 boxers in the 1960s, he reported that most with the syndrome had a static course, there were anecdotal cases of improvement after retirement from boxing, and a small subgroup appeared to have a progressive course greater than expected from aging [2]. Decades later, in 2000, Jordan reviewed the literature and reported that it was unclear whether clinical worsening in boxers reflected a progressive neurodegenerative disease, the aging process superimposed on a fixed neurological injury, or both [17]. At present, it remains inconclusive as to whether the neuropathology or the clinical features of CTE are inexorably progressive. It also remains inconclusive as to whether p-tau causes specific static or progressive clinical features.

LESSONS LEARNED FROM ALZHEIMER’S DISEASE

Studies over the past 20 years have supported the existence of pre-clinical burden of pathology in AD [99–101], and in 2011 a working group published a conceptual framework and operational research criteria for pre-clinical AD [102]. Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]—and it is well established that the pathologic burden of diverse lesions and proteinopathies can be substantial in people who are living independently and are clinically asymptomatic [103–107]. The inflection point or biochemical trigger that separates healthy aging from inexorable progressive neurodegeneration is unknown. Indeed, the conversion from MCI to AD is difficult to predict, and some patients with MCI improve [108]. Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia, and because the correlation between hallmark lesions and the presence and severity of disease is modest, some in the research community have determined that it is important to disambiguate AD into AD-pathological processes and the clinical phases of the disease, which can be termed AD-clinical [102]. Similarly, it seems prudent to disambiguate the neuropathology ascribed to CTE from the diverse purported clinical features.

CONCLUSION

Between the late 1920s and 2009, the clinical features of CTE were described as mostly including gait disturbance, dysarthria, tremor, and cognitive impairment—including dementia. However, mild forms of neuropsychiatric clinical presentations have also been described. It has not been clear in the literature whether CTE is inexorably progressive. Many
cases have been described as being static, not progressive. Moreover, it is now well-established that the pathology of CTE is present in people with other neurodegenerative diseases, such as AD, PD, and multiple system atrophy, so the progression of clinical features in those cases is expected as a direct result of those primary neurodegenerative diseases. There are now several studies illustrating that CTE neuropathology, at the time of death, is limited to Stage I or less in many people [33, 37, 39], suggesting that the kinetics of p-tau accumulation are limited—at least in some people. Further research is needed to determine whether some individuals exposed to repetitive neurotrauma from athletic participation suffer a unique progressive neurodegenerative process, rendered susceptible by the extent of exposure, genetic predisposition, or other factors. At present, there is an absence of scientific evidence to conclude that all or nearly all people with CTE pathology have a progressive neurodegenerative disease, and there is some evidence to support the theory that CTE pathology might not be inexorably progressive. It is not known whether the emergence, course, or severity of clinical symptoms can be predicted by 1) specific combinations of neuropathologies (e.g., p-tau, synaptic dysfunction, amyloid-β, and neuronal loss), 2) thresholds for accumulation of pathology, or 3) regional distributions of pathologies. In addition, factors relating to the resistance and resilience of the human brain to damaging effects of repetitive mild neurotrauma are not understood. When one considers, for example, the enormous neurotrauma exposure of boxers in the early part of the 20th century, and the fact that only 17% of those studied developed a diagnosed neurological syndrome, the resilience and plasticity of the human brain is likely remarkable. Therefore, researchers and clinicians are encouraged to be cautious when considering the clinical symptoms and psychosocial problems of former athletes, civilians, and military veterans, and to be mindful of potential iatrogenic effects of diagnosing a progressive neurodegenerative disease in someone with a psychiatric illness due mostly or entirely to other factors.

In conclusion, preliminary consensus-based neuropathological criteria for CTE were published in 2015 and research criteria for the clinical diagnosis of CTE have been proposed. It has been stated definitively in recent years that CTE is a delayed-onset progressive neurodegenerative disease, although minimal scientific evidence to support this theory is currently available. Some people with the neuropathology of CTE do not appear to have clinical signs or symptoms that are attributable to that pathology, and many do not appear to have a progressive tauopathy. To advance science in this area, it seems prudent to disambiguate the neuropathology of CTE from the possible clinical features.

ACKNOWLEDGMENTS

The authors thank Andrew Gardner, Ph.D. for assistance with the literature review.

George Perry, PhD, is supported by the National Institutes of Health (G12-MD007591).

C. Dirk Keene, MD, PhD is supported by the National Institutes of Health (U01 NS086625 and P50 AG05136) and the Nancy and Buster Alvord Endowment.

Authors’ disclosures available online (http://j-alz.com/manuscript-disclosures/17-0654).

REFERENCES

[1] Martland HS (1928) Punch drunk. J Am Med Assoc 19, 1103-1107.
[2] Roberts A (1969) Brain damage in boxers: A study of prevalence of traumatic encephalopathy among ex-professional boxers. Pitman Medical Scientific Publishing Co., London.
[3] Neubuerger KT, Sinton DW, Denst J (1959) Cerebral atrophy associated with boxing. AMA Arch Neurol Psychiatry 81, 403-408.
[4] Mawdsley C, Ferguson FR (1963) Neurological disease in boxers. Lancet 2, 795-801.
[5] Payne EE (1968) Brains of boxers. Neurochirurgia (Stuttg) 11, 173-188.
[6] Corsellis JA, Bruton CJ, Freeman-Browne D (1973) The aftermath of boxing. Psychol Med 3, 270-303.
[7] Parker HL (1934) Traumatic encephalopathy (‘punch drunk’) of professional pugilists. J Neurol Psychopathol 15, 20-28.
[8] Millspaugh JA (1937) Dementia pugilistica. U S Nav Med Bull 35, 297-303.
[9] Critchley M (1949) Punch-drunk syndromes: The chronic traumatic encephalopathy of boxers. Hommage a Clovis Vincent (ed), Maloine, Paris.
[10] Critchley M (1957) Medical aspects of boxing, particularly from a neurological standpoint. Br Med J 1, 357-362.
[11] Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH (2005) Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 57, 128-134; discussion 128-134.
[12] Omalu BI, DeKosky ST, Hamilton RL, Minster RL, Kamboh MI, Shakir AM, Wecht CH (2006) Chronic traumatic encephalopathy in a national football league player: Part II. Neurosurgery 59, 1086-1092; discussion 1092-1083.
[13] Omalu BI, Hamilton RL, Kamboh MI, DeKosky ST, Bailes J (2010) Chronic traumatic encephalopathy (CTE) in a National Football League Player: Case report and
emerging medicolegal practice questions. *J Forensic Nurs* 6, 40-46.

[14] McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budsen AE, Santini VE, Lee HS, Kubilus CA, Stern RA (2009) Chronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury. *J Neuropathol Exp Neurol* 68, 709-735.

[15] Omalu B, Bailes J, Hamilton RL, Kamboh MI, Hammers J, Case M, Fitzsimmons R (2011) Emerging histomorphologic phenotypes of chronic traumatic encephalopathy in American athletes. *Neurosurgery* 69, 173-183; discussion 183.

[16] McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, Lee HS, Hall G, Wojtowicz SM, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC (2013) The spectrum of disease in chronic traumatic encephalopathy. *Brain* 136, 43-64.

[17] Jordan B (2000) Chronic traumatic brain injury associated with boxing. *Semin Neurol* 20, 179-185.

[18] Gavett BE, Stern RA, McKee AC (2011) Chronic traumatic encephalopathy: A potential late effect of sport-related concussive and subconcussive head trauma. *Clin Sports Med* 30, 179-188, xi.

[19] Stern RA, Riley DO, Daneshvar DH, Nowinski CJ, Cantu RC, McKee AC (2011) Long-term consequences of repetitive brain trauma: Chronic traumatic encephalopathy. *PM R* 3, S460-S467.

[20] Stern RA, Daneshvar DH, Baugh CM, Seichepine DR, Montenigro PH, Riley DO, Fritts NG, Stamm JM, Robbins CA, McHale L, Simkin I, Stern TD, Alvarez VE, Goldstein LE, Budson AE, Kowall NW, Nowinski CJ, Cantu RC, McKee AC (2013) Clinical presentation of chronic traumatic encephalopathy. *Neurology* 81, 1122-1129.

[21] Montenigro PH, Baugh CM, Daneshvar DH, Mox J, Budson AE, Au R, Katz D, Cantu RC, Stern RA (2014) Clinical subtypes of chronic traumatic encephalopathy: Literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. *Alzheimers Res Ther* 6, 68.

[22] Omalu B (2014) Chronic traumatic encephalopathy. *Prog Neurool Surg* 28, 38-49.

[23] Omalu B, Bailes J, Hammers JL, Fitzsimmons RP (2010) Chronic traumatic encephalopathy, suicides and parasuicides in professional American athletes: The role of the forensic pathologist. *Am J Forensic Med Pathol* 31, 130-132.

[24] Baugh CM, Stamm JM, Riley DO, Gavett BE, Shenton ME, Lin A, Nowinski CJ, Cantu RC, McKee AC, Stern RA (2012) Chronic traumatic encephalopathy: Neurodegeneration following repetitive concussive and subconcussive brain trauma. *Brain Imaging Behav* 6, 244-254.

[25] Gavett BE, Cantu RC, Shenton M, Lin AF, Nowinski CJ, McKee AC, Stern RA (2011) Clinical appraisal of chronic traumatic encephalopathy: Current perspectives and future directions. *Carr Opin Neurol* 24, 525-531.

[26] Eloise A, Libard S, Leino M, Popova SN, Alafuozof I (2016) Altered Proteins in the Aging Brain. *J Neuropathol Exp Neurol* 75, 316-325.

[27] Castellani RJ, Perry G, Iverson GL (2015) Chronic effects of mild neurotrauma: Putting the cart before the horse? *J Neuropathol Exp Neurol* 74, 493-499.

[28] Davis GA, Castellani RJ, McCrory P (2015) Neurodegeneration and sport. *Neurosurgery* 76, 643-656.

[29] Iverson GL, Gardner AJ, McCrory P, Zafonte R, Castellani RJ (2015) A critical review of chronic traumatic encephalopathy. *Neurosci Biobehav Rev* 56, 276-293.

[30] McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I, Pearl DP, Stein TD, Vonsattel JP, Stewart W, Tripodis Y, Cryer JF, Bieniek KF, Dams-O’Connor K, Alvarez VE, Gordon WA, TBI/CTE group (2016) The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. *Acta Neuropathol* 131, 75-86.

[31] Fournier CN, Gearing M, Upadhyayula SR, Klein M, Glass JD (2015) Head injury does not alter disease progression or neuropathological outcomes in ALS. *Neurology* 84, 1788-1795.

[32] Puvenna V, Engeler M, Banjara M, Brennan C, Schreiber P, Dadas A, Bahraim A, Solanki J, Bandypadhyay A, Morris JK, Bernick C, Ghosh C, Rapp E, Bazzar J, Janigro D (2016) Is phosphorylated tau unique to chronic traumatic encephalopathy? Phosphorylated tau in epileptic brain and chronic traumatic encephalopathy. *Brain Res* 1630, 225-240.

[33] Koga S, Dickson DW, Bieniek KF (2016) Chronic traumatic encephalopathy pathology in multiple system atrophy. *J Neuropathol Exp Neurol* 75, 963-970.

[34] Gao AF, Ramsay D, Twose R, Rogaevea E, Tator C, Hazrati LN (2017) Chronic traumatic encephalopathy-like neuropathological findings without a history of trauma. *Int J Pathol Clin Res* 3, 050.

[35] Cray JF, Trojanowski JQ, Schneider JA, Abisambra JA, Ahner EL, Alafuozof I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukult W, Mackenzie IR, Masliah E, McKee A, Mntone TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL, W, Wisniewski T, Woltjer RL, Yamada M, Nelson PT (2014) Primary age-related tauopathy (PART): A common pathology associated with human aging. *Acta Neuropathol* 128, 755-766.

[36] Kovacs GG, Furrer I, Grinberg LT, Alafuozof I, Attems J, Budka H, Cairns NJ, Cray JF, Duykaerts C, Ghezzi B, Halliday GM, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray NE, Nelson PT, Takashahi H, Trojanowski JQ, Ansorge O, Arzberger T, Baboric A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaconne G, Hatampa KJ, Heale H, Hof PR, Hofer M, Hortobagyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kovali E, Kril JJ, Mann DM, Mates R, McKee AC, McLean C, Mlenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemuller A, Schneider JA, Schultz C, Seeley E, Seihian D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tocalin MC, Troncoso JC, Vinters HV, Wess S, Wharton SB, White CL, Wisniewski T, Wiltzie J, Yamada M, Dickson DW (2016) Aging-related tau astrophylogia (ARTAG): Harmonized evaluation strategy. *Acta Neuropathol* 131, 87-102.

[37] Ling H, Holton JL, Shaw K, Davey K, Lashley T, Revess T (2015) Histological evidence of chronic traumatic encephalopathy in a large series of neurodegenerative diseases. *Acta Neuropathol* 130, 891-893.

[38] Bieniek KF, Ross OA, Cormier KA, Walton RL, Soto-Otoloza A, Johnston AE, deSaro P, Boylan KB, Graff-Radford NR, Wszolek ZK, Rademakers R, Boeve BF, McKee AC, Dickson DW (2015) Chronic traumatic
encephalopathy pathology in a neurodegenerative disorder brain bank. *Acta Neuropathol* **130**, 877-889.

[39] Noy S, Krawitz S, Del Bigio MR (2016) Chronic traumatic encephalopathy-like abnormalities in a routine neuropathology service. *J Neuropathol Exp Neurol* **75**, 1145-1154.

[40] Castellani RJ, Perry G (2014) The complexities of the pathology-pathogenesis relationship in Alzheimer disease. *Biochem Pharmacol* **88**, 671-676.

[41] Hazrati LN, Tartaglia MC, Diamandis P, Davis KD, Green RE, Wennberg R, Wong JC, Ezerins L, Tator CH (2013) Absence of chronic traumatic encephalopathy in retired football players with multiple concussions and neurological symptomatology. *Front Hum Neurosci* **7**, 222.

[42] Ling H, Kara E, Revesz T, Lees AJ, Plant GT, Martino D, Houlden H, Hardy J, Holton JL (2014) Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer. *Acta Neuropathol Commun* **2**, 24.

[43] McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, Perl DP, Hedley-Whyte ET, Price B, Sullivan C, Morin P, Lee HS, Kubilus CA, Daneshvar DH, Wulff M, Budse AE (2010) TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. *J Neuropathol Exp Neurol* **69**, 918-929.

[44] Ling H, Morris HR, Neal JW, Lees AJ, Hardy J, Holton JL, Revesz T, Williams DD (2017) Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. *Acta Neuropathol* **133**, 337-352.

[45] Grinberg LT, Anghinah R, Nascimento CF, Amaro E, Leite RP, Martin Mda G, Naslavsky MS, Takada LT, Filho WJ, Pasqualucci CA, Nitrini R (2016) Chronic traumatic encephalopathy presenting as Alzheimer’s disease in a retired soccer player. *J Alzheimers Dis* **54**, 169-174.

[46] Jordan BD (2013) The clinical spectrum of sport-related traumatic brain injury. *Nat Rev Neurol* **9**, 222-230.

[47] Victoroff J (2013) Traumatic encephalopathy: Review and provisional research diagnostic criteria. *NeuroRehabilitation* **32**, 211-224.

[48] Roberts GW, Allsop D, Bruton C (1990) The occult aftermath of boxing. *J Neurol Neurosurg Psychiatry* **53**, 373-378.

[49] Johnson J (1969) Organic psychosyndromes due to boxing. *Br J Psychiatry* **115**, 45-53.

[50] Iverson GL (2016) Suicide and chronic traumatic encephalopathy. *J Neuropsychiatry Clin Neurosci* **28**, 9-16.

[51] Worstel HS, Shura RD, Brenner LA (2013) Chronic traumatic encephalopathy and suicide: A systematic review. *Biomed Res Int* **2013**, 424280.

[52] Iverson GL (2014) Chronic traumatic encephalopathy and risk of suicide in former athletes. *Br J Sports Med* **48**, 162-165.

[53] Maroon JC, Winkelman R, Bost J, Amos A, Mathyssek C, Miele V (2015) Chronic traumatic encephalopathy in contact sports: A systematic review of all reported pathological cases. *PLoS One* **10**, e0117338.

[54] Webner D, Iverson GL (2016) Suicide in professional American football player in the past 95 years. *Brain Inj* **30**, 1718-1721.

[55] Lehman EJ, Hein MJ, Gersic CM (2016) Suicide mortality among retired National Football League players who played 5 or more seasons. *Am J Sports Med* **44**, 2486-2491.

[56] Kendler KS, Thornton LM, Gardner CO (2001) Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. *Am J Psychiatry* **158**, 582-586.

[57] Kendler KS, Thornton LM, Gardner CO (2000) Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the “kindling” hypothesis. *Am J Psychiatry* **157**, 1243-1251.

[58] Monroe SM, Harkness KL (2005) Life stress, the “kindling” hypothesis, and the recurrence of depression: Considerations from a life stress perspective. *Psychol Rev* **112**, 417-445.

[59] Binder EB, Nemeroff CB (2010) The CRF system, stress, depression and anxiety-insights from human genetic studies. *Mol Psychiatry* **15**, 574-588.

[60] Hauger RL, Rissbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM (2009) Role of CRF receptor signaling in stress vulnerability, and depression. *Ann N Y Acad Sci* **1179**, 120-143.

[61] McGuffin P, Knight J, Breen G, Brewster S, Boyd PR, Craddock N, Gill M, Korszun A, Maier W, Middleton L, Mors O, Owen MJ, Perry J, Preisig M, Reich T, Rice J, Rietschel M, Jones L, Sham P, Farmer AE (2005) Whole genome linkage scan of recurrent depressive disorder from the depression network study. *Hum Mol Genet* **14**, 3337-3345.

[62] Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of major depression: Review and meta-analysis. *Am J Psychiatry* **157**, 1552-1562.

[63] Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, Gillespie CF, Berg T, Evcses M, Newport DJ, Stowe ZN, Heim CM, Nemeroff CB, Schwartz A, Cubells JF, Ressler KJ (2008) Influence of child abuse on adult depression: Moderation by the corticotropin-releasing hormone receptor gene. *Arch Gen Psychiatry* **65**, 190-200.

[64] Heim C, Newport DJ, Meltzko T, Miller AH, Nemeroff CB (2008) The link between childhood trauma and depression and anxiety-insights from human genetic studies. *Psychoneuroendocrinology* **33**, 693-710.

[65] Heim C, Bradley B, Meltzko T, Deveau TC, Musselman DL, Nemeroff CB, Ressler KJ, Binder EB (2009) Effect of childhood trauma on adult depression and neuroendocrine function: Sex-specific moderation by CRH receptor 1 gene. *Front Behav Neurosci* **3**, 1-10.

[66] Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR, Gordon E, Kemp AH, Williams LM (2009) Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. *Mol Psychiatry* **14**, 681-695.

[67] Farmer AE, McGuffin P (2003) Humiliation, loss and other types of life events and difficulties: A comparison of depressed subjects, healthy controls and their siblings. *Psychoneuroendocrinology* **28**, 157-171.

[68] Frisén RH, Wittchen HU, Pfister H, Lieb R (2002) Life events and changes in the course of depression in young adults. *Eur Psychiatry* **17**, 241-253.

[69] Kendler KS, Hettema JM, Butera F, Gardner CO, Prescott CA (2003) Life event dimensions of loss, humiliation, entrapment, and danger in the prediction of onsets of major depression and generalized anxiety. *Arch Gen Psychiatry* **60**, 789-796.

[70] Kendler KS, Karkowski LM, Prescott CA (1999) Causal relationship between stressful life events and the onset of major depression. *Am J Psychiatry* **156**, 837-841.
[71] Atkinson JH, Slater MA, Patterson TL, Grant I, Garfin SR (1991) Prevalence, onset, and risk of psychiatric disorders in men with chronic low back pain: A controlled study. Pain 45, 111-121.

[72] Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS (1997) Chronic pain-associated depression: Antecedent or consequence of chronic pain? A review. Clin J Pain 13, 116-137.

[73] Wilson KG, Eriksson MY, D’Eon JL, Mikail SF, Emery PC (2002) Major depression and insomnia in chronic pain. Clin J Pain 18, 77-83.

[74] Campbell LC, Clauw DJ, Keefe FJ (2003) Persistent pain and depression: A biopsychosocial perspective. Biol Psychiatry 54, 399-409.

[75] McWilliams LA, Cox BJ, Enns MW (2003) Mood and anxiety disorders associated with chronic pain: An examination in a nationally representative sample. Pain 106, 127-133.

[76] Hung CI, Liu CY, Fuh JL, Juang YY, Wang SJ (2006) Comorbid migraine is associated with a negative impact on quality of life in patients with major depression. Cephalalgia 26, 26-32.

[77] Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM (2000) Headache and major depression: Is the association specific to migraine? Neurology 54, 308-313.

[78] Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM (2003) Comorbidity of migraine and depression: Investigating potential etiology and prognosis. Neurology 60, 1308-1312.

[79] Sheftell FD, Atlas SJ (2002) Migraine and psychiatric comorbidity: From theory and hypotheses to clinical application. Headache 42, 934-944.

[80] Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2002) Migraine and psychiatric comorbidity: From theory and hypotheses to clinical application. Headache 42, 934-944.

[81] Lin EH, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, Ludman EJ, Young BA, Williams LH, McCulloch DK, Von Korff M (2010) Depression and advanced complications of diabetes: A prospective cohort study. Diabetes Care 33, 264-269.

[82] Naranjo DM, Fisher L, Arean PA, Hessler D, Mullan J (2004) Depressive symptoms after CABG surgery: A meta-analysis. J Psychiatr Pract 10, 289-305.

[83] Yeap BB (2014) Hormonal changes and their impact on cognition and mental health of ageing men. Maturitas 79, 227-235.

[84] Khera M (2013) Patients with testosterone deficit syndrome and depression. Arch Exp Urol 66, 729-736.

[85] Almeida OP, Ford AH, Flicker L, Hankey GJ, Yeap BB, Clancy P, Gollelde J (2014) Angiogenesis inhibition and depression in older men. J Psychiatry Neurosci 39, 200-205.

[86] Ravven S, Bader C, Azar A, Rudolph J (2013) Depressive symptoms after CABG surgery: A meta-analysis. Harv Rev Psychiatry 21, 59-69.

[87] Ayerbe L, Ayis S, Wolfe CD, Rudd AG (2013) Natural history, predictors and outcomes of depression after stroke: Systematic review and meta-analysis. Br J Psychiatry 202, 14-21.

[88] Leung YW, Flora DB, Gravelly S, Irvine J, Carney RM, Grace SL (2012) The impact of premorbid and postmorbid depression onset on mortality and cardiac morbidity among patients with coronary heart disease: Meta-analysis. Psychosom Med 74, 786-801.

[89] Meng L, Chen D, Yang Y, Zheng Y, Hui R (2012) Depression increases the risk of hypertension incidence: A meta-analysis of prospective cohort studies. J Hypertens 30, 842-851.

[90] Gothe F, Enache D, Wahlund LO, Winblad B, Crisby M, Lokk J, Aarsland D (2012) Cerebrovascular diseases and depression: Epidemiology, mechanisms and treatment. Panminerva Med 54, 161-170.

[91] Naarding P, Beekman AT (2011) Vascular depression: Where do we go from here? Expert Rev Neurother 11, 77-83.

[92] Djamshidian A, Friedman JH (2014) Anxiety and depression in Parkinson’s disease. Curr Treat Options Neurol 16, 285.

[93] Bruce JM, Bhatta R, Westervelt HJ, Davis J, Williams V, Tremont G (2008) Neuropsychological correlates of self-reported depression and self-reported cognition among patients with mild cognitive impairment. J Geriatr Psychiatry Neurol 21, 34-40.

[94] Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K (2006) Depressive symptoms, vascular disease, and mild cognitive impairment: Findings from the Cardiovascular Health Study. Arch Gen Psychiatry 63, 273-279.

[95] Kosteniuk JG, Morgan DG, O’Connell ME, Crossley M, Kirk A, Stewart NJ, Karunanayake CP (2014) Prevalence and covariates of elevated depressive symptoms in rural memory clinic patients with mild cognitive impairment or dementia. Dement Geriatr Cogn Dis Extra 4, 209-220.

[96] Raskind MA (2008) Diagnosis and treatment of depression comorbid with neurologic disorders. Am J Med 121, S28-S37.

[97] Carrol EJ (1936) Punch-drunk. Am J Med Sci 191, 706-712.

[98] Morris JC, Storandt M, McKeel DW Jr, Rubin EH, Price JL, Grant EA, Berg L (1996) Cerebral amyloid deposition and diffuse plaques in “normal” aging: Evidence for presymptomatic and very mild Alzheimer’s disease. Neurology 46, 707-719.

[99] Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Marsh DC, McIntyre LM (1998) Neuropathological and neuropsychological changes in “normal” aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57, 1168-1174.

[100] Morris JC (1999) Is Alzheimer’s disease inevitable with age?: Lessons from clinicopathologic studies of healthy aging and very mild Alzheimer’s disease. J Clin Invest 104, 1171-1173.

[101] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7, 280-292.

[102] Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837-1844.
[104] Mormino EC (2014) The relevance of beta-amyloid on markers of Alzheimer’s disease in clinically normal individuals and factors that influence these associations. *Neuropsychol Rev* 24, 300-312.

[105] Vanharanta H, Malmivaara A, Korpi J (1989) [Back pain]. *Duodecim* 105, 105-113.

[106] Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA (2011) Amyloid-beta associated cortical thinning in clinically normal elderly. *Ann Neurol* 69, 1032-1042.

[107] Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. *Acta Neuropathol* 115, 437-444.

[108] Petersen RC (2011) Clinical practice. Mild cognitive impairment. *N Engl J Med* 364, 2227-2234.